Australia markets open in 2 hours 25 minutes

Longboard Pharmaceuticals, Inc. (LBPH)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.87+0.11 (+1.91%)
As of 3:34PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close5.76
Open5.90
Bid5.76 x 1000
Ask5.88 x 1000
Day's range5.76 - 6.01
52-week range5.76 - 18.95
Volume12,957
Avg. volume29,696
Market cap101.054M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.62
Earnings date04 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est29.75
  • GlobeNewswire

    Longboard Pharmaceuticals Appoints Life Sciences Executive Dr. Jane Tiller to Board of Directors

    SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Jane Tiller, MBChB, FRCPsych, to its board of directors. "We are thrilled to further strengthen the deep expertise of our Board with the addition of Dr. Tiller. Jane brings knowledge across multiple therapeutic areas including neuroscience, and a d

  • GlobeNewswire

    Longboard Pharmaceuticals to Participate in Upcoming Investor Conferences

    SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will participate in the following conferences: Guggenheim Healthcare Talks Neuro/Immunology Virtual Conference: Hosting investor meetings Monday, November 15 – Tuesday, November 16, 2021Evercore ISI 4th Annual HealthCONx Vir

  • GlobeNewswire

    Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial Results

    Successfully completed multiple ascending dose (MAD) portion of a Phase 1 clinical trial for LP352, a potential treatment for seizures associated with a broad range of severe epilepsiesInitiating a Phase 1b/2a clinical trial evaluating LP352 in approximately 50 participants with developmental and epileptic encephalopathies (DEEs) in Q1 2022IND-enabling preclinical studies for LP143 and LP659 ongoingContinuing to strengthen key expertise and leadership SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) --